

## CZECH REPUBLIC

### Recent and planned developments in pharmaceutical policies 2017

#### Special topic: hospital medicines

##### CHANGES IN PRICING

- **01/01/2018:** Exclusion of Greece from ERP
- Planned amendment:
  - Raise of price extreme to 30 per cent (currently reference price is excluded if it is 20 or more per cent below the average of second and third lowest reference price)

##### CHANGES IN REIMBURSEMENT

- Ongoing 2<sup>nd</sup> and 3<sup>rd</sup> waves of complex reimbursement reviews
- **01/01/2018:** Change of annual co-payment ceilings:
  - 1000 CZK for patients under 18 years and above 65 years old (2500 CZK before)
  - 500 CZK for patient above 70 years (2500 CZK before).
  - 5000 CZK for other patient (no change)
- Planned amendment:
  - Raise of price extreme to 30 per cent (currently reference price is excluded if it is 20 or more per cent below the average of second and third lowest reference price)
  - Modification of procedure for medicinal product bonus reimbursement
  - Modification of highly innovative medicinal product reimbursement procedure

##### OTHERS CHANGES

- **01/12/2017:** Implementation of the amendment relating to re-export regulation, mandatory MAHs delivery reports and pharmacy-distributor-MAH relations adjustment
- **01/01/2018:** Mandatory electronic prescription
- **01/01/2018:** Reimbursement of vaccination against human papillomavirus for boys; vaccination against invasive meningococcal infections, pneumococcal infections, invasive disease caused by Haemophilus influenzae type b and influenza for specific types of patients; vaccination against pneumococcal infections for persons above 65 years following by the recommendation of the National Immunization Committee

##### SPECIAL TOPIC: HOSPITAL MEDICINES

- **Procurement:**
  - By hospitals themselves or groups of hospitals (rare)
  - Since 01/07/2017, some hospitals purchase contracts must be listed in public Registry of Contracts
  - Real purchasing prices might differ due to application of reverse bonuses or similar discounts (not published)
  - Negotiations and tendering procedures
- **Financing/reimbursement:**
  - Agreements between hospitals and health insurance companies
  - Hospital pharmaceutical formulary - these are fully reimbursed
- **HTA:** N/A
- **Interface management:**
  - During in-patient care all pharmacotherapy is provided by the hospital
  - Prescribed medicines may be changed in the out-patient sector and vice versa if not disallowed by prescription restrictions
- **Main challenges in 2017:** Discussion about optional above-standard care
- **In-patient pharmaceutical expenditure:** 15.20 per cent of hospital cost [www.uzis.cz](http://www.uzis.cz) (2015) (estimate to 19 per cent of out-patient pharma., incl. out-patient hospital care)